Trending...
- NOW OPEN - New Single Family Home Community in Manalapan
- $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
- Kintetsu And Oversee Announce New Partnership
~ Congruence Therapeutics, a biotechnology company focused on developing small molecule correctors to rescue aberrant protein function, has announced their participation in the International Congress of Parkinson's Disease and Movement Disorders 2024 Meeting. The event will take place from September 27th to October 1st, 2024 in Philadelphia, PA.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
- As Paris Hilton Reclaims Her Icon Status, "Pretty Pop Star" Reemerges to Battle the Age of AI Music
- Food Journal Magazine Is Shaping the Conversation Around Los Angeles Food in 2026
- MITSUYA PLATING Expands ONE-STOP Service for US-based Medical Device, Semiconductor and Aerospace Manufacturers
- Chester County Tile Expert Reveals Top Home Value Mistakes Homeowners Make During Remodeling Projects
- Star Trek, Goonies, Ninja Turtles Stars Among First Main Wave Of FAN EXPO Philadelphia Celebrities
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
Filed Under: Business
0 Comments
Latest on The PennZone
- Metavalis Launches Massive Community Coat Drive in Branson to Support Local Residents
- Jim Breuer is Coming to The Eichelberger Performing Arts Center This May
- Peak Exteriors to Expand Its Services to Premium Outdoor Lighting Installation
- Ashley Wineland To Release Fiery Full-length Album "Wineland"
- Robert D. Botticelli Promoted to Century Fasteners Corp. – Director of Sales
- Openchannelflow Wins Web Excellence Award for Outstanding Digital Experience
- STS Capital Partners' Andy Harris Co-Authors 'The Extraordinary Exit,' A Practical Guide for Business Owners Considering a Sale
- One-Click Pro Audio for Streamers: "VoiceSterize" Automates Noise Reduction & Mastering on Mac
- Sole Publishing Announces Essential Parenting Book for Families Navigating the Teen Years
- From Factory Floor to Community Heart: The Rebel Spirit of Wisconsin's Wet Wipe Innovators
- UK Financial Ltd Lists MayaFund (MFUND) ERC-20 Token on CATEX Exchange Ahead of Planned ERC-3643 Upgrade
- Benjamin Ross Group Has Secured Financing for a Company with a Sale Price of $1,050,000
- Denver Apartment Finders Launches Revamped Denver Tech Center Apartment Location Page
- Roblox and Solsten Alliances; a Stronger Balance Sheet and Accelerated Growth Through AI, Gaming, and Strategic Partnerships for Super League: $SLE
- Boston Industrial Solutions' Natron® 512N Series UV LED Ink Earns CPSIA Certification
- Power Business Solutions Announces Joint Venture with EIG Global Trust to Deliver Data Center Financial Solutions
- Scoop Social Co. Partners with Fairmont Hotels & Resorts to Elevate Summer Guest Experiences with Italian Inspired Gelato & Beverage Carts
- Buildout Launches Native Email Marketing Feature, Expanding Its End-to-End CRE Platform
- New Saxophone Prize Honors Astronaut Ronald E. McNair, First To Play Sax In Space
- Building a $145M AI-Powered Marine Platform as Listings Surge, Global Expansion Begins, OTH Shares Trade at a Discount: Off The Hook YS (N Y S E: OTH)